为肌层浸润性尿路上皮癌的辅助治疗建立成本效益模型的挑战、考虑因素和方法：重点关注 nivolumab 与安慰剂的比较

IF 2.9 4区医学 Q2 HEALTH CARE SCIENCES & SERVICES

Journal of Medical Economics Pub Date : 2024-02-22 DOI:10.1080/13696998.2024.2322394

Siguroli Teitsson, Thor-Henrik Brodtkorb, Murat Kurt, Miraj Y. Patel, Tayla Poretta, Christopher Knight, Farzam Kamgar, Stephen Palmer

引用次数: 0

摘要

介绍开发决策分析模型的挑战和注意事项，该模型可用于评估与监测相比，对高危癌症患者进行 nivolumab 辅助治疗的成本效益。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Challenges, considerations, and approaches for developing a cost-effectiveness model for the adjuvant treatment of muscle-invasive urothelial carcinoma: with a spotlight on nivolumab versus placebo

To present challenges and considerations for the development of a decision analytic model for evaluating the cost-effectiveness of adjuvant nivolumab compared with surveillance in patients with hig...

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Journal of Medical Economics HEALTH CARE SCIENCES & SERVICES-MEDICINE, GENERAL & INTERNAL

CiteScore

4.50

自引率

4.20%

发文量

122

期刊介绍： Journal of Medical Economics'' mission is to provide ethical, unbiased and rapid publication of quality content that is validated by rigorous peer review. The aim of Journal of Medical Economics is to serve the information needs of the pharmacoeconomics and healthcare research community, to help translate research advances into patient care and be a leader in transparency/disclosure by facilitating a collaborative and honest approach to publication. Journal of Medical Economics publishes high-quality economic assessments of novel therapeutic and device interventions for an international audience